news
Ilka Diester wins Boehringer Ingelheim’s FENS Award 2012 for Exceptional Research in Neuroscience
16 July 2012 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Ilka Diester...
List view / Grid view
Boehringer Ingelheim
news
Boehringer Ingelheim pursuing health care innovation – new collaboration with Healthrageous, Inc
10 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is concentrating on new business models...
news
Boehringer Ingelheim establishes translational research collaboration with Harvard University
9 July 2012 | By Boehringer Ingelheim
"We are very pleased to sponsor the joint research programs..."
news
Boehringer Ingelheim announces changes to Board of Managing Directors
5 July 2012 | By Boehringer Ingelheim
Joachim Hasenmaier to lead new Board Division Consumer Healthcare and Animal Health...
news
Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride
28 June 2012 | By Boehringer Ingelheim
Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly…
news
First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
news
Boehringer Ingelheim BioXcellence
18 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business...
news
AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
news
Lilly and Boehringer Ingelheim present data at the 72nd American Diabetes Association Scientific Sessions® from Phase II studies comparing investigational novel basal insulin to insulin glargine
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
news
FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
news
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
news
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
4 June 2012 | By Boehringer Ingelheim
LUX-Lung 3 results highlighted at the official ASCO Press Conference...
news
Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects
1 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new partnership with ammado...
news
Boehringer Ingelheim expands development capacities with new technical centre
31 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility...
news
Boehringer Ingelheim further strengthens animal health presence in China
30 May 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Taizhou China Medical City announced the signing of an agreement...
